1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Oncology Biosimilars Revenue
1.4 Market Analysis by Type
1.4.1 Global Oncology Biosimilars Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 mAb
1.4.3 Immunomodulators
1.4.4 Hematopoietic Agents
1.4.5 G-CSF
1.4.6 Others
1.5 Market by Application
1.5.1 Global Oncology Biosimilars Market Share by Application: 2021-2026
1.5.2 Retail Pharmacies
1.5.3 Hospital Pharmacy
1.5.4 Online Pharmacy
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Oncology Biosimilars Market
1.8.1 Global Oncology Biosimilars Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Oncology Biosimilars Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Oncology Biosimilars Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Oncology Biosimilars Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Oncology Biosimilars Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Oncology Biosimilars Sales Volume Market Share by Region (2015-2020)
3.2 Global Oncology Biosimilars Sales Revenue Market Share by Region (2015-2020)
3.3 North America Oncology Biosimilars Sales Volume
3.3.1 North America Oncology Biosimilars Sales Volume Growth Rate (2015-2020)
3.3.2 North America Oncology Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Oncology Biosimilars Sales Volume
3.4.1 East Asia Oncology Biosimilars Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Oncology Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Oncology Biosimilars Sales Volume (2015-2020)
3.5.1 Europe Oncology Biosimilars Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Oncology Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Oncology Biosimilars Sales Volume (2015-2020)
3.6.1 South Asia Oncology Biosimilars Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Oncology Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Oncology Biosimilars Sales Volume (2015-2020)
3.7.1 Southeast Asia Oncology Biosimilars Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Oncology Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Oncology Biosimilars Sales Volume (2015-2020)
3.8.1 Middle East Oncology Biosimilars Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Oncology Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Oncology Biosimilars Sales Volume (2015-2020)
3.9.1 Africa Oncology Biosimilars Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Oncology Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Oncology Biosimilars Sales Volume (2015-2020)
3.10.1 Oceania Oncology Biosimilars Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Oncology Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Oncology Biosimilars Sales Volume (2015-2020)
3.11.1 South America Oncology Biosimilars Sales Volume Growth Rate (2015-2020)
3.11.2 South America Oncology Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Oncology Biosimilars Sales Volume (2015-2020)
3.12.1 Rest of the World Oncology Biosimilars Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Oncology Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Oncology Biosimilars Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Oncology Biosimilars Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Oncology Biosimilars Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Oncology Biosimilars Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Oncology Biosimilars Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Oncology Biosimilars Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Oncology Biosimilars Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Oncology Biosimilars Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Oncology Biosimilars Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Oncology Biosimilars Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Oncology Biosimilars Sales Volume Market Share by Type (2015-2020)
14.2 Global Oncology Biosimilars Sales Revenue Market Share by Type (2015-2020)
14.3 Global Oncology Biosimilars Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Oncology Biosimilars Consumption Volume by Application (2015-2020)
15.2 Global Oncology Biosimilars Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Oncology Biosimilars Business
16.1 Celltrion
16.1.1 Celltrion Company Profile
16.1.2 Celltrion Oncology Biosimilars Product Specification
16.1.3 Celltrion Oncology Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Teva Pharmaceutical Industries Ltd
16.2.1 Teva Pharmaceutical Industries Ltd Company Profile
16.2.2 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Specification
16.2.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 STADA Arzneimittel AG
16.3.1 STADA Arzneimittel AG Company Profile
16.3.2 STADA Arzneimittel AG Oncology Biosimilars Product Specification
16.3.3 STADA Arzneimittel AG Oncology Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Biocon
16.4.1 Biocon Company Profile
16.4.2 Biocon Oncology Biosimilars Product Specification
16.4.3 Biocon Oncology Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Sandoz International
16.5.1 Sandoz International Company Profile
16.5.2 Sandoz International Oncology Biosimilars Product Specification
16.5.3 Sandoz International Oncology Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Dr. Reddys Laboratories
16.6.1 Dr. Reddys Laboratories Company Profile
16.6.2 Dr. Reddys Laboratories Oncology Biosimilars Product Specification
16.6.3 Dr. Reddys Laboratories Oncology Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 BIOCAD
16.7.1 BIOCAD Company Profile
16.7.2 BIOCAD Oncology Biosimilars Product Specification
16.7.3 BIOCAD Oncology Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Pfizer
16.8.1 Pfizer Company Profile
16.8.2 Pfizer Oncology Biosimilars Product Specification
16.8.3 Pfizer Oncology Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Intas Pharmaceuticals
16.9.1 Intas Pharmaceuticals Company Profile
16.9.2 Intas Pharmaceuticals Oncology Biosimilars Product Specification
16.9.3 Intas Pharmaceuticals Oncology Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Apotex
16.10.1 Apotex Company Profile
16.10.2 Apotex Oncology Biosimilars Product Specification
16.10.3 Apotex Oncology Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Oncology Biosimilars Manufacturing Cost Analysis
17.1 Oncology Biosimilars Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Oncology Biosimilars
17.4 Oncology Biosimilars Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Oncology Biosimilars Distributors List
18.3 Oncology Biosimilars Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Oncology Biosimilars (2021-2026)
20.2 Global Forecasted Revenue of Oncology Biosimilars (2021-2026)
20.3 Global Forecasted Price of Oncology Biosimilars (2015-2026)
20.4 Global Forecasted Production of Oncology Biosimilars by Region (2021-2026)
20.4.1 North America Oncology Biosimilars Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Oncology Biosimilars Production, Revenue Forecast (2021-2026)
20.4.3 Europe Oncology Biosimilars Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Oncology Biosimilars Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Oncology Biosimilars Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Oncology Biosimilars Production, Revenue Forecast (2021-2026)
20.4.7 Africa Oncology Biosimilars Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Oncology Biosimilars Production, Revenue Forecast (2021-2026)
20.4.9 South America Oncology Biosimilars Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Oncology Biosimilars Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Oncology Biosimilars by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Oncology Biosimilars by Country
21.2 East Asia Market Forecasted Consumption of Oncology Biosimilars by Country
21.3 Europe Market Forecasted Consumption of Oncology Biosimilars by Countriy
21.4 South Asia Forecasted Consumption of Oncology Biosimilars by Country
21.5 Southeast Asia Forecasted Consumption of Oncology Biosimilars by Country
21.6 Middle East Forecasted Consumption of Oncology Biosimilars by Country
21.7 Africa Forecasted Consumption of Oncology Biosimilars by Country
21.8 Oceania Forecasted Consumption of Oncology Biosimilars by Country
21.9 South America Forecasted Consumption of Oncology Biosimilars by Country
21.10 Rest of the world Forecasted Consumption of Oncology Biosimilars by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer